Physician profile
James Rone
NPI 1982692844
$5,511.33
in general payments reported to CMS, 2019-2025
67 companies · $826 in 2025
The $826 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,263 · 2020: $618 · 2021: $736 · 2022: $671 · 2023: $730 · 2024: $666 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,222.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $656.51 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $565.36 | 2019-2025 | Evenity, Tepezza, Repatha |
| Lilly USA, LLC | $390.44 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $386.52 | 2019-2022 | |
| Ibsa Pharma INC. | $256.18 | 2019-2025 | Tirosint, Tirosint, Licart |
| Abbvie INC. | $227.13 | 2019-2025 | Synthroid |
| Corcept Therapeutics | $189.91 | 2019-2023 | Korlym |
| Xeris Pharmaceuticals, INC. | $179.29 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Radius Health, INC. | $170.61 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.62 | 2019-2025 | Jardiance, Synjardy |
| Sanofi-Aventis U.S. LLC | $147.77 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $147.67 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $119.65 | 2021-2025 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $104.69 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $92.74 | 2019-2025 | Strensiq |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.